This report was first published by Endpoints News. To see the original version, click here
Attempts by the White House to curry industry support for legislation that would codify last year’s voluntary drug pricing deals are being ignored by some drugmakers who believe there’s little to negotiate.
Two sources familiar with the White House’s engagement with industry said that a number of companies have declined invitations to review draft legislative text. It was not immediately clear which companies have declined, after at least four companies met with administration officials earlier this month.
您已阅读15%（600字），剩余85%（3439字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。